Shots:

• Sirnaomics has completed the preclinical study of STP125G assessing its safety & efficacy in non-human primate (NHP) models to support IND submission for conducting P-I trial in cardiovascular disease indications
• In the study (N=4), STP125G showed dose-dependent silencing at 1mg/kg, 3mg/kg & 10mg/kg, with max. efficacy at 10mg/kg at wk.4 that remained for another 9wks. Safety was favorable at SC dosing of 50mg/kg, 100mg/kg & 250mg/kg, with similar silencing efficacy to 10mg/kg
• STP125G is a second siRNA therapy that targets ApoC3 mRNA and is developed using Sirnaomics’ GalAhead mxRNA technology for treating cardiovascular diseases

Ref: Sirnaomics | Image: Sirnaomics

Related News:- Sirnaomics Reports the Completion Patient Dosing of STP707 in P-I Study for Treatment of Multiple Solid Tumors

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com